Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ReCOV
- Development stage
- Phase 3
- Lead developer
- Recbio
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
ReCOV is a recombinant protein subunit vaccine developed for the prevention of COVID-19. It is designed to induce an immune response against SARS-CoV-2, the virus responsible for COVID-19, by presenting a portion of the viral spike protein to stimulate protective immunity. The vaccine uses recombinant technology to produce the antigenic component and is administered as an injection. ReCOV has been evaluated in clinical trials for its safety and efficacy in preventing COVID-19.
- Brand names
- ReCOV
- Other names
- RBD-Fc/NTD-Fc vaccinetwo-component recombinant COVID-19 vaccinerecombinant trimeric NTD and RBD two-component SARS-CoV-2 subunit vaccine
02
Targets
S1-NTD (SARS-CoV-2 spike S1 N-terminal domain)RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on ReCOV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ReCOV.